Corrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization

  • Front Pharmacol. 2023 Jan 18:13:1109002. doi: 10.3389/fphar.2022.1109002.
Mingming Fan  1  2 ,  Huijuan Xiao  2  3 ,  Dingyun Song  2 ,  Lili Zhu  2 ,  Jie Zhang  1 ,  Xinran Zhang  2  4 ,  Jing Wang  5 ,  Huaping Dai  2 ,  Chen Wang  1  2  5
Affiliations
  • 1. Department of Respiratory Medicine, The Second Hospital of Jilin University, Jilin, China.
  • 2. Department of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, Capital Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • 3. Department of Pulmonary and Critical Care Medicine, China-Japan Friendship School of Clinical Medicine, Peking University, Beijing, China.
  • 4. Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
  • 5. State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
PMID: 36744209 DOI: 10.3389/fphar.2022.1109002
Abstract

[This corrects the article DOI: 10.3389/fphar.2022.848435.].

Keywords
AKEX0011; macrophage polarization; pirfenidone; pulmonary fibrosis; silicosis.
Products